pson201605276k.htm
UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549
 
 
FORM 6-K
 
 
REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934
 
 
For the month of May 2016
 
 
PEARSON plc
(Exact name of registrant as specified in its charter)

 
N/A

 
(Translation of registrant's name into English)

 
80 Strand

London, England WC2R 0RL

44-20-7010-2000
(Address of principal executive office)

 
 
Indicate by check mark whether the Registrant files or will file annual reports
under cover of Form 20-F or Form 40-F:


 
 
Form 20-F X                                                Form 40-F


 
 
Indicate by check mark whether the Registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934


 
 
Yes                                              No X
 

 

PEARSON PLC
(the "Company")
 
Non-executive director

 
The Company hereby announces that Vivienne Cox, Pearson's senior independent director, has been appointed as a non-executive director of GlaxoSmithKline plc, and a member of its Corporate Responsibility Committee, with effect from 1 July 2016.
 
This notification is made in accordance with LR 9.6.14.
 
 
SIGNATURE
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.



 
 
PEARSON plc

 
 
 
Date: 27 May 2016
 
 
 
By: /s/ NATALIE DALE

 
-----------------------
Natalie Dale
Deputy Company Secretary